|
- CleanCap® Reagent AG | TriLink BioTechnologies
CleanCap ® Reagent AG is TriLink’s patented co-transcriptional capping reagent for in vitro transcription of 5’ capped mRNA resulting in a Cap 1 structure CleanCap has shown to provide up to 98% capping efficiency
- CleanCap ® mRNA capping technology - TriLink BioTech
Our newest analog, CleanCap ® M6, offers the most effective co-transcriptional method to date, increasing protein expression by over 30% when compared to the previous analogs
- CleanCap ® Reagent AG (3 OMe) - (N-7413) - TriLink BioTech
CleanCap ® Reagent AG (3′ OMe) is designed for the co-transcriptional capping of messenger RNAs (mRNAs) to produce an optimal Cap 1
- Revolutionary Co-Transcriptional Capping Technology - Syntezza
CleanCap technology is a proprietary, co-transcriptional 5’ capping solution that generates a natural Cap 1 structure Compared to traditional methods, CleanCap greatly improves efficiency and quality, while decreasing the cost associated with employing cap analogs and providing the highest quality mRNA 5’ cap structure
- CleanCap ® AG (3′ OMe) CleanScript™ IVT Kit - (K-7413)
The kit contains an IVT buffer for co-transcriptional capping with the supplied CleanCap analog The buffer is proprietary and formulated based on TriLink’s CleanScript IVT method to increase yield and lower dsRNA formation
- CleanCap M6 outperforms previous analogs - TriLink BioTech
TriLink has revolutionized mRNA capping strategies with its one-pot CleanCap capping solutions generating the optimal Cap1 structure with more than 95% efficiency Shortens therapeutic mRNA manufacturing process time per batch by nearly a week compared to enzymatic capping
- Simplicity meets superior mRNA with CleanCap ® IVT kits
TriLink’s CleanCap ® AG (3′ OMe) CleanScript™ IVT Kit is designed to streamline your mRNA synthesis and enhance your results significantly This comprehensive kit includes all necessary components to produce mRNAs by in vitro transcription (IVT) with CleanCap ® co-transcriptional capping
- CleanCap® EGFP mRNA | TriLink BioTechnologies
CleanCap ® Reagent AG produces a base-modified Cap-1 mRNA, which shows superior in vivo activity compared to Cap-0 mRNA produced by legacy capping methods such as mCap or anti-reverse cap analog (ARCA)
|
|
|